Navigation Links
Prasco Selected as GSK's Generics Marketing and Distribution Agent
Date:3/11/2009

Fluticasone Propionate Nasal Spray (FLONASE(R)) will be the first product marketed under this arrangement

MASON, Ohio, March 11 /PRNewswire/ -- Prasco Laboratories, announced today it has entered into a marketing and distribution agreement with GlaxoSmithKline (NYSE: GSK). FLONASE(R) (fluticasone propionate) Nasal Spray is the first product to be marketed under this agreement. Prasco, as GSK's agent and on GSK's behalf, will solicit orders for, and distribute Fluticasone Propionate Nasal Spray to all trade classes in the U.S. under a GSK/Prasco label.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090311/CL81889)

"We are especially proud to have established this relationship with GlaxoSmithKline, a global leader in the research-based pharmaceutical industry," said Prasco Chief Executive Officer E. Thomas Arington. "We look forward to working with GSK to provide more choices for patients in the generics market."

"GlaxoSmithKline is always looking for opportunities to increase access to our medicines for patients," said Stan Hull, GlaxoSmithKline Senior Vice President, U.S. Pharmaceuticals. "The arrangement with Prasco, a known leader in the generics market, allows GSK to expand participation in the generic market in a new way."

Fluticasone Propionate Nasal Spray is AB-rated, therapeutically equivalent and substitutable for the brand FLONASE Nasal Spray. Fluticasone Propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.

FLONASE(R) is a registered trademark of Glaxo Group Limited, UK.

About Prasco

Prasco's mission is to provide both quality products and significant cost-savings to the consumer. Prasco's goal is to provide patients with brand sameness through Prasco Authorized Generics, which are brand-products sold under the Prasco private label. Prasco's executive team has extensive experience working within both the brand and generic industries. A centerpiece of the company's corporate capabilities is its sales/marketing and business development teams. Prasco's product line is currently sold through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.

The company operates from a 160,000 sq. ft. administrative office and warehouse facility and has complete control over product distribution management systems--including DEA-approved facilities for Schedule II-V controlled drug products.

About GSK:

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com


'/>"/>
SOURCE Prasco Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prasco to Distribute Generic Forms of Dorzolamide Hydrochloride-Timolol Maleate and Dorzolamide Hydrochloride Ophthalmic Solutions (Comparable to Mercks COSOPT(R) and TRUSOPT(R) Ophthalmic Solutions)
2. Brooke Franchise Corporation Announces Selected July Results
3. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
4. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
5. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
6. Fry Construction Selected for High-Profile Medical Imaging Project
7. Meth Project Advertisements Selected for National Prevention Campaign
8. Eight Graduate Nursing Students Selected to Receive The California Endowment-AACN Minority Nurse Faculty Scholarship
9. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
10. SAIC Selected to Support the U.S. Military Theater Medical Information Program-Joint
11. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
(Date:12/5/2016)... Atlanta, GA (PRWEB) , ... ... ... information technology and security executive networking and relationship-marketing firm, announced today that ... for the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include ...
(Date:12/5/2016)... Novato, CA (PRWEB) , ... December 05, 2016 ... ... company, has extended its partnership with leading global lifestyle design firm kathy ireland® ... , Worldwise® and kathy ireland® Worldwide entered into an exclusive licensing agreement three ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... announced that the company will provide alerting technology to Central Illinois Health ... awarded $1.7 million in federal funds as the sole sub-recipient participating with ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... and Gateway Health proudly announce a dynamic collaboration that will ... members with specific high risk needs. In an ... of consumers, Wellbridge combines technology and population expertise with a ... daily behaviors and lifestyle. ... , , "Dealing ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, ... Sankyo) today announced preliminary safety and efficacy data ... investigational oral selective MDM2 inhibitor, suggesting that DS-3032 ... including relapsed/refractory acute myeloid leukemia (AML) and high-risk ... escalation part of the phase 1 study of DS-3032 ...
Breaking Medicine Technology: